Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2026-05-12 16:09:09 ET · period of report 2026-05-11 · accession 0001653881-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-05-12 16:09 | 2026-05-11 | RCUS | Goeltz II Robert C. | CFO | S - Sale | $25.63 | -7,763 | 84.2K | -8% | -$199.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-11 | S | D | 7,763 | $25.63 | 84,161 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. (F2) Includes the unvested portion of the reporting person's RSU grants. |